Post Market Surveillance Requirements. SAMED Regulatory Conference 2 December 2015

Similar documents
MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL

Guide to Incident Reporting for In-vitro Diagnostic Medical Devices

Guide to Incident Reporting for General Medical Devices and Active Implantable Medical Devices

Guidelines on the Keeping of Records in Respect of Medicinal Products when Conducting a Retail Pharmacy Business

UPDATE: Regulatory Framework for Medical Devices in South Africa. SAMED Annual Conference. 14 June 2018 Jerry Molokwane

GHTF SG2 Guidance: Group work output presentation

Guidance for registered pharmacies preparing unlicensed medicines

NEW JERSEY. Downloaded January 2011

MINIMUM CRITERIA FOR REACH AND CLP INSPECTIONS 1

SFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use

Determining and Reporting Adverse Events vs. Product Complaints

GUIDELINES ON A MEDICAL DEVICES VIGILANCE SYSTEM

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER STERILE PRODUCT PREPARATION IN PHARMACY PRACTICE TABLE OF CONTENTS

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

Pharmacovigilance Office of Product Review

GUIDELINES ON MEDICAL DEVICES CLINICAL INVESTIGATIONS: SERIOUS ADVERSE EVENT REPORTING

Guideline on good pharmacovigilance practices (GVP)

REVISED FIP BASEL STATEMENTS ON THE FUTURE OF HOSPITAL PHARMACY

Brachytherapy-Radiopharmaceutical Therapy Quality Management Program. Rev Date: Feb

National Health Regulatory Authority Kingdom of Bahrain

The Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE

Medical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:

Medication Management Policy and Procedures

MEDICINES CONTROL COUNCIL

SECTION HOSPITALS: OTHER HEALTH FACILITIES

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES

Clinical. Medication Errors and Medicine Defect Reporting SOP. Document Control Summary. Contents

Safety Reporting in Clinical Research Policy Final Version 4.0

CHAPTER:2 HOSPITAL PHARMACY. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Incident Management June 2018

CARE FACILITIES PART 300 SKILLED NURSING AND INTERMEDIATE CARE FACILITIES CODE SECTION MEDICATION POLICIES AND PROCEDURES

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Colorado Board of Pharmacy Rules pertaining to Collaborative Practice Agreements

NORTH CAROLINA. Downloaded January 2011

Procedure to Allow Nursing Staff to Dispense Leave and Discharge Medication

FINAL DOCUMENT. Global Harmonization Task Force

MEDICAL DEVICE GUIDANCE

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Remediation, Resolution and Outcomes

Recommendations from Florida Assisted Living Association

Unlicensed Medicines Policy Document

Guideline on good pharmacovigilance practices (GVP)

Legal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences

PERSONAL PROTECTIVE EQUIPMENT (PPE) GUIDELINES

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers

Pre-registration. e-portfolio

Licensed Pharmacy Technicians Scope of Practice

Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018

Prepublication Requirements

THE BOARD OF THE EURASIAN ECONOMIC COMMISSION RESOLUTION. dated December 22, 2015 N 174

The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements

The policy applies to all SHS employees involved in direct patient care and medical staff.

The Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

Corporate Induction: Part 2

MANAGEMENT AND ADMINISTRATION OF MEDICATION. 1. The Scope and Role of the Senior Registered Nurse (SRN)

3/9/2010. Objectives. Pharmacist Role in Medication Safety and Regulatory Compliance

PHARMACY SERVICES/MEDICATION USE

MEDICINES CONTROL COUNCIL

Non-Medical Prescribing Passport. Reflective Log And Information

Thanks to Anne C. Byrne, RN, Medical Monitor at Northwest Georgia Regional Hospital. This presentation was developed from one she designed for that

Law on Medical Devices

Version Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13

Patients Own Medications Policy

STANDARDS Point-of-Care Testing

Procedure 26 Standard Operating Procedure for Controlled Drugs in homes within NHS Sutton CCG

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Drug and Medical Device Registration FAQ

Human Research Governance Review Policy

Reaccreditation of a Dispensing / Pharmacy Assistant programme, Buttercups Training Ltd.

PHYSIOTHERAPY ACT STANDARDS AND DISCIPLINE REGULATIONS

Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING

Medical Device Reporting for Manufacturers

Safety in the Pharmacy

FINAL STATUS DOCUMENT

Human Samples in Research

Inspection decision making framework

Signatory Name: Roche Diagnostics Australia Pty Limited

MEDICINES CONTROL COUNCIL

APPROVED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R Effective May 16, 2018

Changing Requirements for Devices//Device Constituent Parts in Combination Products

Clinical Risk Management: Agile Development Implementation Guidance

What does governance look like in homecare?

International Pharmaceutical Federation Fédération internationale pharmaceutique. Standards for Quality of Pharmacy Services

Standards of Practice Non-Prescription Drugs A Report to the National Association of Pharmacy Regulatory Authorities

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31

Good Pharmacy Practice in Spanish Community Pharmacy

HEALTH & SAFETY POLICY CONTENTS

May 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).

Therefore the provision of medicines is an area for which a Community regulatory framework should be properly supervised to ensure full and

Registration of a new pharmacy premises

STANDARD OPERATING PROCEDURE

a remote pharmacy is not necessarily intended to provide permanent??? how do we make it so that it may be only for limited duration.

Chapter 13. Documenting Clinical Activities

Policies Approved by the 2017 ASHP House of Delegates

MEDICINES CONTROL COUNCIL

NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)

3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

Transcription:

Post Market Surveillance Requirements SAMED Regulatory Conference 2 December 2015

Topics Surveillance & Vigilance Adverse Events Reportable Adverse Events Reporting Adverse Events Time frames Exemptions from Reporting Adverse events Non-recall Actions Recall & withdrawals

Surveillance & Vigilance The purpose of medical device vigilance is to improve the health and safety of patients, users, and others by reducing the likelihood of adverse events being repeated. This can be achieved by: evaluating reported adverse events disseminating information that could be used to prevent or minimise the consequences of adverse events, where appropriate modifying the device or IVD removing the medical device or IVD from the market

Complaints & Incidents Feed into QMS Adverse Event Reportable / Non reportable?

Reportable Adverse Event 3 basic criteria Adverse event (AE) occurred Your medical device is associated with the AE The event led or might lead to death or serious injury, or might lead to death or serious injury if it were to occur again

Adverse Event An adverse event is an event that may lead to: death, or a serious injury or serious deterioration to a patient, user or other person, including a life-threatening illness or injury permanent impairment of a body function permanent damage to a body structure a condition necessitating medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure.

Near adverse event might have led to a death or serious injury but.. due to the timely intervention of a health professional a death or serious injury did not occur. For an event to be defined as a near adverse event, it is sufficient that: an event associated with the device happened if the event occurred again, it might lead to death or serious injury testing or examination of the device or the information supplied with the device, or scientific literature indicated some factor that could lead to a death or serious injury.

Device Incident User & Health professional s opinion Information concerning previous similar events Other information available All health professionals, users, patients, hospitals, wholesalers, ARs, companies are encourage to report events associated with use of medical devices

AE Reporting Exemptions 8 Exemption rules However, these rules do NOT apply when: a device, event or issue specifically identified by the Council as an issue that requires close monitoring applicants of devices that are affected will be notified by the Council when this occurs an adverse event normally subject to a reporting exemption, where a change in trend (usually an increase in frequency) or pattern is identified adverse events associated with user error, as the Council may use this data to identify trends with similar products that may lead to recommendations for: corrective action for the device revising the labelling or Instructions for Use identifying a need for increased user education. If a manufacturer believes an exemption rule applies to reporting an adverse event, the reasons for not reporting the event should be documented.

Rule No. Exemption Rules 1. Deficiency of a new device found by the user prior to its use Regardless of the existence of provisions in the Instruction for Use provided by the manufacturer, deficiencies of devices that will be always detected by the user and where no serious injury has occurred, do not need to be reported. Please note: If the device is used the exemption does not apply the event must be reported. 2. Adverse event caused solely by patient conditions When the manufacturer has information that the root cause of the adverse event is due to patient condition, the event does not need to be reported. These conditions could be pre-existing or occurring during device use. To justify not reporting, the manufacturer should have information available to conclude that the device performed as intended and did not cause or contribute to a death or serious injury. A person qualified to make a medical judgement would accept the same conclusion.

Rule No. Exemption Rules 3. Service life of the medical device When the only cause for the adverse event was that the device exceeded its service life and the failure mode is not unusual, the adverse event does not need to be reported. Assessment of whether an event is exempt from reporting under this rule must be based on the information in the master record, on the label or in Instructions for Use for the device. 4. Protection against a fault functioned correctly Adverse events that did not lead to serious injury or death, because a design feature protected against a fault becoming a hazardous situation (in accordance with relevant standards or documented design inputs) do not need to be reported.

Rule No. Exemption Rules 5. Remote likelihood of occurrence of death or serious injury Adverse events that could lead, but have not yet led, to death or serious injury, but have a remote likelihood of causing death or serious injury, and which have been established and documented as acceptable after risk assessment do not need to be reported. If an adverse event resulting in death or serious injury occurs, the adverse event is reportable and a reassessment of the risk is necessary. If reassessment determines that the risk remains remote, previous reports of near incidents of the same type do not need to be reported retrospectively. Decisions not to report subsequent failures of the same type must be documented. Please note: A change in the trend (usually an increase in frequency) of these non-serious outcomes must be reported.

Rule No. Exemption Rules 6. Expected and foreseeable side effects that are documented in manufacturer s Instructions for Use or labelling Documentation, including the risk assessment, for the particular side effect should be available in the device master record prior to the occurrence of adverse events. The manufacturer cannot conclude in the face of events that they are foreseeable unless there is prior supporting information. 7. Adverse events described in an advisory notice Adverse events that occur after the manufacturer has issued an advisory notice need not be reported individually if they are specified in the notice. Advisory notices include removals from the market, corrective actions, and product recalls. The manufacturer should provide a summary report, the content and frequency of which should be agreed with the Council.

Rule No. Exemption Rules 8. Reporting exemptions granted by the Council Upon request by the applicant, common and well-documented events may be exempted by the Council from reporting or changed to periodic reporting on a case by case basis.

Timeline to submit AE Reports Regulation 24 of the Act, the period in which a person in relation to whom a kind of medical device is included in the Register must give information to the Council is: if the information relates to an event or other occurrence that represents a serious threat to public health - 48 hours after the person becomes aware of the event or occurrence; and if the information relates to an event or other occurrence that led to the death, or a serious deterioration in the state of health, of a patient, a user of the device, or another person -10 calendar days after the person becomes aware of the event or occurrence; and if the information relates to an event or other occurrence a recurrence of which might lead to the death, or a serious deterioration in the state of health, of a patient, a user of the device, or another person -30 days after the person becomes aware of the event or occurrence.

Post incident investigation & assessment Possible Outcomes Regulatory action including inspection / audit of manufacturer Recall of the devices to: remove the devices from supply in South Africa allow correction at the user s site the issue of a Safety Alert where there is a need to reinforce the manufacturer s Instructions for Use to those responsible for the use of the device or those affected by the problem product improvement for problems that are not safety-related - carried out by the manufacturer report on the Council website and/or appropriate communication

Non Recall Actions Action Safety Alert Description Intended to provide information on safe use of devices, as distinct from recall action, which addresses product deficiencies Issued to provide additional advice to health professionals in situations where the device, although meeting all specifications and therapeutic indications, its use could present an unreasonable risk of substantial harm if certain specified precautions or advice are not observed. For example, specific precautions about the longevity of an implanted medical device Product Notification Product Withdrawal Product Recovery User information Issue of precautionary information about a device in a situation that is unlikely to involve significant adverse health consequences HRC's removal from supply or use of devices for reasons not related to their quality, safety or performance The HRC recovers devices that have been manufactured or imported but not yet supplied to the market. For example, recovery of devices in a warehouse Generally conducted by the HRC in response to issues with the use of a medical device Includes in-house sessions, seminars and improved educational materials such as posters

Recall of Medical Devices & IVDs The holder of a certificate of registration (HCR)/parallel importer/distributor should inform the Registrar of all the quality defects that may result in a recall of a medicine/medical device/ivds and the HCR/parallel importer/distributor together with the medicines regulatory authority may decide if there is a need to recall or not.

Information Required for assessment of a Recall In the case of medical devices and IVDs recall provisions must be applied when: the medical device does not meet the Essential Principles conformity assessment procedures have not been applied to the medical device The HCR/parallel importer should make available to the MCC all the relevant information regarding the recall on the report form provided as Annex1. The information required may be included in Annex 1 but not limited to it only. The applicant / HCR/ AR MUST immediately on becoming aware of a problem notify the Registrar before or upon initiating a recall

Stages of a Recall

3 Classes of Recalls and 3 Types of Recalls CLASSIFICATION Class I (Safety related) DESCRIPTION Product defects are defective/dangerous/ potentially life-threatening that predictably or probably could result in serious health risk/adverse events or even death and could cause permanent debilitating health issues. Class II (Safety related) Class III (Non-Safety related) Product defects could cause illness, temporary or medically reversible adverse health problem or mistreatment and the recovery of the patient is likely Product defects may not pose a significant hazard to health, but are defective and are unlikely to cause any adverse health reaction, withdrawal may be initiated for other reasons, or which do not comply with the requirements of Act 101 of 1965 in terms of the requirements of printed packaging material, product specification, labeling, etc.

3 Classes of Recalls and 3 Types of Recalls TYPE Type A DESCRIPTION designed to reach all suppliers of medicines/medical devices/ivds (all distribution points) i.e. wholesalers throughout the country, directors of hospital services (private as well as state hospitals), retail outlets, doctors, nurses, pharmacists, authorised prescribers and dispensers and individual customers or patients through media release (radio, television, regional and national press). Action: Recall letter to all distribution points plus media release Type B Type C designed to reach wholesalers throughout the country, directors of hospital services (private as well as state hospitals), retail outlets, doctors, nurses, pharmacists, authorised prescribers and dispensers. Action: Recall letter to all distribution points. designed to reach wholesale level and other distribution points (e.g. pharmacies, doctors, hospitals) this can be achieved by means of a representatives calling on wholesalers and/or retail outlets. If it is known where the product in question had been distributed to, specific telephone calls or recalls letters to arrange for the return of the product could be made. Action: Specific telephone calls, recall letters to/representatives calling at distribution points if known where the medicines/medical devices/ivds have been distributed.

Recall Letter Contents On company s letterhead and signed by Authorised Representative. The heading should indicate that it is an Urgent Medicine/Medical/Devices/IVDs Recall. The heading should also indicate the classification and type of the recall. Where applicable the name of product, dosage form, strength, registration number, pack size, batch number(s), expiry date and any other relevant information necessary to allow absolute identification. Nature of the defect (be brief and to the point). Urgency of the action. Reason for the action (reason for recall). Indication of a health risk (this should also state exactly what the product may do if taken / used, i.e. side- effects). Provide specific information on what should be done in respect of the recalled medicine/medical device/ivd. Method of recovery or product correction, which will be used. Where necessary a follow-up communication shall be sent to those who failed to respond to the initial recall communication. Contact telephone number and facsimile return numbers (preferably toll free) A request to retain the letter in a prominent position for one month in case stock is in transit (where applicable). Where recalled stock has been distributed to a limited number of hospitals and the recall letter is not to be sent to all hospitals in the province, the letter should include the following: If any of the recalled stock could have been transferred from your hospital to another, please let that hospital know or alternatively inform our company so that we can make contact with the hospital supplied from your hospital.

Post Recall Requirements 1. Provide interim report on effectiveness of recall - two weeks after the implementation of the recall (or at other agreed times) 2. Final Recall report within 30 days of the recall Information required Details on the investigation into the cause of the defect. The corrective actions proposed/implemented and the dates of implementation to prevent a recurrence of the problem. The extent of distribution of the relevant batch in South Africa as well as to the international market. The success of the recall i.e. quantity of stock returned, corrected, outstanding, etc. Confirmation, where applicable, (e.g. hospitals, pharmacists, doctors, customers, other international regulatory authorities / holder of distribution authorization in the foreign country) that the recall letter was received. The method of destruction or disposal of the recalled goods.

Follow-up Action Evaluation on the effectiveness of the recall and an investigation of the reason for the recall and corrective actions taken to prevent a recurrence of the problem. The Medicines Control Officer shall evaluate the reports received from the recalling site and an assessment made of the effectiveness of the recall action On completion of a recall or during the process of a recall, the recalling site is requested to provide details of the corrective actions and time lines proposed to prevent a recurrence of the problem which gave rise to the recall. Where the nature of the problem and appropriate corrective actions are not apparent, investigation and in some cases QMS audits may be necessary. Apparent follow-up actions will be taken by the MCC or Inspectorate and Law Enforcement directorate on behalf of the MCC as directed by Council. Once the recall has been handled satisfactory, the MCC will determine closure of the recall.

Jane Rogers Strategic Healthcare Solutions (Pty) Ltd. +27 (0)82 898 4493 JaneRogers@StratHealthcare.co.za 26 PO Box 1396, Morningside, Sandton, 2057 South Africa Reg. 2013/104488/07